Drug-Eluting Balloons Market Outlook 2025–2033: Innovations in Cardiovascular Treatment
The Drug-Eluting Balloons (DEB) market is rapidly gaining attention as an advanced interventional cardiology solution. Designed to deliver anti-proliferative drugs directly to the arterial wall, DEBs combine the benefits of balloon angioplasty with localized drug therapy. They are widely used in treating coronary artery disease (CAD) and peripheral artery disease (PAD) —two conditions that represent leading causes of global mortality. Unlike traditional bare-metal stents (BMS) or drug-eluting stents (DES) , DEBs provide a stent-less therapeutic alternative, reducing long-term complications such as restenosis, late thrombosis, and vessel inflammation. The technology is especially useful in small vessel disease, bifurcation lesions, and in-stent restenosis, where conventional methods face limitations. Between 2025 and 2033, the DEB market is expected to witness robust growth, fueled by rising cardiovascular disease prevalence, an aging population, technological advancements,...